<

Coinbase Pro Lists Gitcoin (GTC), Enzyme (MLN), and Amp (AMP)

The largest crypto exchange in the U.S. Coinbase Pro has announced today that its lists Gitcoin (GTC), Enzyme (MLN), and Amp (AMP). The tokens will be available in Coinbase’s supported jurisdictions with the exception of GTC in New York. Trading will begin on or after 9AM Pacific Time (PT)Thursday, June 10, if liquidity conditions are met.

“Once sufficient supply of GTC, MLN and AMP  is established on the platform, trading on our GTC-USDMLN-USD and AMP-USD order books will launch in three phases, post-only, limit-only and full trading. If at any point one of the new order books does not meet our assessment for a healthy and orderly market, we may keep the book in one state for a longer period of time or suspend trading as per our Trading Rules.” the exchange said.

Gitcoin (GTC) is an Ethereum token that enables community governance of the Gitcoin platform. The platform is designed to fund and coordinate open source development by novel means such as quadratic funding. As of June 2021, Gitcoin has facilitated over $21 million in grants and bounties for open source developers.

MLN is an Ethereum token that powers Enzyme (formerly known as Melon Protocol), a protocol that aims to facilitate on-chain asset management for the DeFi ecosystem. MLN allows users to build, share, and explore DeFi investment strategies (called “vaults”) while filtering by historical performance and risk profiles. MLN is used to pay for various functions throughout the vault creation process and investment lifecycle.

Amp is an Ethereum token that aims to “collateralize payments on the Flexa Network, making them instant and secure.” If a BTC or ETH payment fails due to unconfirmed or long transaction times “the Amp collateral can instead be liquidated to cover losses” while the vendor receives payment in fiat, potentially providing greater assurances to both parties.

Read more:

Join us on Telegram

Follow us on Twitter

Follow us on Facebook

You might also like

LATEST NEWS

LASTEST NEWS